Reshoring explores why bringing life sciences manufacturing back to the United States has become a strategic priority rather than a reactive response. The episode examines the forces driving reshoring decisions, including supply chain disruptions, geopolitical risk, increased regulatory scrutiny, and the need for greater operational control across pharmaceutical, biotech, and medical device manufacturing.
The discussion focuses on what it actually takes to reshore successfully, from regulatory strategy and facility readiness to quality system implementation, validation, and workforce planning. Rather than framing reshoring as a simple relocation, this episode highlights it as an integrated transformation that requires careful planning to balance speed, compliance, and long-term supply chain resilience in a highly regulated environment.
